Salmeterol
Generic name
Salmeterol
Brand name
ATC Code
R03AC12
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Bronchial dilation (long-acting) |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
There is insufficient data known about the use of salmeterol in children aged under 4 years. Before prescribing salmeterol, a bronchodilating response should be confirmed and documented by making an FEV1 measurement before and after beta-2 mimetics. An alternative to the lung function measurements in children aged less than 6 years is a good clinical response to a short-acting beta-2-agonist. Use of long-acting beta-2-agonist should be prescribed in the secondary care sector as per the guidelines of the NHG (Dutch College of General Practitioners) and the SKL (Paediatric Pulmonary Disease Section).
Do not use as treatment for acute asthma attacks.
Administration: Serevent dosing aerosol can be administered in combination with the following holding chambers: Volumatic (age > 4 years)
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ADRENERGICS, INHALANTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Alpha- and beta-adrenoreceptor agonists | ||
|---|---|---|
| R03AA01 | ||
| Selective beta-2-adrenoreceptor agonists | ||
|---|---|---|
| R03AC13 | ||
| R03AC02 | ||
| R03AC03 | ||
| Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics | ||
|---|---|---|
| R03AK08 | ||
| R03AK11 | ||
| R03AK10 | ||
| R03AK07 | ||
| R03AK06 | ||
| Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids | ||
|---|---|---|
| R03AL01 | ||
| R03AL02 | ||
References
- NVK sectie Kinderlongziekten, Medicamenteuze behandeling van astma bij kinderen. Herziene richtlijnen van kinderlongartsen, 2007
- GlaxoSmithKline BV, SPC Serevent aerosol (RVG 33735), www.cbg-meb.nl, Geraadpleegd 27 oktober 2010, http://db.cbg-meb.nl/IB-teksten/h33735.pdf
Changes
Therapeutic Drug Monitoring
Overdose
